Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - trandolapril, quantity: 4 mg - capsule - excipient ingredients: croscarmellose sodium; sodium stearylfumarate; titanium dioxide; gelatin; maize starch; povidone; lactose monohydrate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfuntion post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - trandolapril, quantity: 2 mg - capsule - excipient ingredients: brilliant blue fcf; maize starch; sodium stearylfumarate; erythrosine; lactose monohydrate; allura red ac; titanium dioxide; povidone; gelatin; croscarmellose sodium; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfuntion post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - trandolapril, quantity: 1 mg - capsule - excipient ingredients: titanium dioxide; croscarmellose sodium; gelatin; erythrosine; povidone; sunset yellow fcf; lactose monohydrate; sodium stearylfumarate; maize starch; brilliant blue fcf; allura red ac; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfuntion post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - trandolapril, quantity: 0.5 mg - capsule - excipient ingredients: povidone; titanium dioxide; maize starch; croscarmellose sodium; sodium stearylfumarate; gelatin; lactose monohydrate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfuntion post myocardial infarction (ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - enalapril maleate, quantity: 20 mg - tablet - excipient ingredients: croscarmellose sodium; hypromellose; lactose monohydrate; sodium stearylfumarate; maleic acid - hypertension ,enalapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. ,congestive heart failure ,enalapril is indicated for the treatment of all degrees of symptomatic heart failure. in such patients, it is recommended that enalapril be administered together with a diuretic. ,left ventricular dysfunction ,all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35 percent, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - enalapril maleate, quantity: 5 mg - tablet - excipient ingredients: croscarmellose sodium; hypromellose; sodium stearylfumarate; maleic acid; lactose monohydrate - hypertension ,enalapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. ,congestive heart failure ,enalapril is indicated for the treatment of all degrees of symptomatic heart failure. in such patients, it is recommended that enalapril be administered together with a diuretic. ,left ventricular dysfunction ,all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35 percent, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - enalapril maleate, quantity: 10 mg - tablet - excipient ingredients: lactose monohydrate; hypromellose; maleic acid; croscarmellose sodium; sodium stearylfumarate - hypertension ,enalapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. ,congestive heart failure ,enalapril is indicated for the treatment of all degrees of symptomatic heart failure. in such patients, it is recommended that enalapril be administered together with a diuretic. ,left ventricular dysfunction ,all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35 percent, irrespective of the presence or severity of obvious symptoms of heart failure.

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - trandolapril (unii: 1t0n3g9crc) (trandolaprilat - unii:rr6866vl0o), verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - trandolapril 4 mg - trandolapril and verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension (see dosage and administration ). in using trandolapril and verapamil hydrochloride extended-release tablets, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that trandolapril does not have similar risk (see warnings - neutropenia/agranulocytosis ). trandolapril and verapamil hydrochloride extended-release tablets are contraindicated in patients who are hypersensitive to any ace inhibitor or verapamil. because of the verapamil component, trandolapril and verapamil hydrochloride extended-release tablets are contraindicated in: because of the trandolapril component, trandolapril and verapamil hydrochloride extended-release tablets are contraindicated in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme (ace) inhibitor. do not co-administer aliskiren with trandolapril and verapamil hydrochloride extended-release tablets in patients with diabetes (see precautions - drug interactions ). trandolapril and verapamil hydrochloride extended-release tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer trandolapril and verapamil hydrochloride extended-release tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see warnings ).

United States - English - NLM (National Library of Medicine)

greenstone llc - trandolapril (unii: 1t0n3g9crc) (trandolaprilat - unii:rr6866vl0o), verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - trandolapril 2 mg - trandolapril/verapamil hydrochloride er tablets are indicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension (see dosage and administration ). in using trandolapril/verapamil hydrochloride er tablets, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that trandolapril does not have similar risk (see warnings - neutropenia/agranulocytosis ). trandolapril/verapamil hydrochloride er tablets are contraindicated in patients who are hypersensitive to any ace inhibitor or verapamil. because of the verapamil component, trandolapril/verapamil hydrochloride er tablets are contraindicated in: - severe left ventricular dysfunction (see warnings ). - hypotension (systolic pressure less than 90 mmhg) or cardiogenic shock. - sick sinus syndrome (exce

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate 2.5 mg - enalapril maleate tablets are indicated for the treatment of hypertension. enalapril maleate tablets are effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate tablets and thiazides are approximately additive. enalapril maleate tablets are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate tablets improve symptoms, increase survival, and decrease the frequency of hospitalization (see clinical pharmacology , heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤ 35 percent), enalapril maleate tablets decrease the rate of development of overt heart failure and decrease the incidence of hospitalization for heart failure (see clinical pharmacology , heart failure, mortality tria